In December 2025, the AI-powered clinical research platform Manifold raised $18 million in a Series B funding round. The investment was led by Reach Capital, with participation from SilverArc Capital, Industry Ventures, and existing investors TQ Ventures and Calibrate Ventures.
The company is led by co-founders Vinay Seth Mohta (CEO) and Vivek Mohta (President). Manifold is modernizing the antiquated research computing infrastructure that powers modern science, specifically targeting the $2 trillion life sciences market.
The research ecosystem currently suffers from a massive data fragmentation problem. Manifold addresses this with its “Agent OS,” a platform that unifies multimodal datasets and automates complex manual workflows—from cohort building and genomic data harmonization to clinical trial design. By allowing research institutions like the Broad Institute of MIT and Harvard to deploy AI agents directly on their own cloud, Manifold ensures absolute data sovereignty and compliance while reducing “time-to-insight” from months to minutes.
The new capital will be used to expand its platform capabilities and scale its data ecosystem to support the next generation of precision medicine and biopharma R&D.
Market Signal
- From Generic to Domain-Specific: This $18M round validates that general-purpose AI cannot solve the structural challenges of clinical research. Manifold’s “Agent OS” creates a specialized layer that understands scientific governance and biological data, forming a deep defensive moat against horizontal competitors.
- Modernizing Research Computing: Manifold is effectively building the “Modern Data Stack” for science. By integrating directly into scientific tools like Jupyter and R, they are shifting the industry from slow, bespoke software builds toward a standardized, high-velocity research environment.
- The Sovereignty Advantage: In the highly regulated world of clinical trials, “Bring Your Own Cloud” is a winning sales strategy. Manifold’s focus on data sovereignty allows top-tier hospitals and biopharma giants to adopt AI without the risk of exposing sensitive patient or proprietary research data.
Key Details
- Company: Manifold
- Funding: $18M Series B
- Headquarters: Newton, MA
- Founders: Vinay Seth Mohta (CEO), Vivek Mohta
- Use Case: AI-powered clinical research and multimodal data harmonization
